Loading
Cardiovascular Disease and Adiposity / Adipokines, Inflammation, and Metabolic Diseases · Journal article
Pediatric Research · August 11, 2026
The material analysed did not support any firm read.
This is a narrative commentary that introduces adipolin as a potential biomarker of vascular injury in obese children and discusses the rationale for the Jin et al. study on adipolin and endothelial dysfunction. It presents background on obesity epidemiology, inflammatory mechanisms, and conflicting evidence for adipolin levels but does not report original empirical findings or provide a quantitative synthesis.
Journal article. Children aged 5–14 years with obesity; obese mice (in cited preclinical work).
In 2021, 93.1 million children aged 5–14 years were diagnosed with obesity Obese adults have reduced adipolin levels, but recent evidence suggests children with obesity have elevated adipolin levels Adipolin has been found to improve insulin resistance and reduce proinflammatory gene expression in obese mice
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This commentary identifies adipolin as a candidate biomarker worthy of investigation in paediatric obesity and vascular dysfunction, but does not itself provide evidence to guide clinical practice. Clinicians should await results from the primary studies cited (particularly Jin et al.) before considering adipolin measurement in clinical care.
This is a commentary on another study, not a primary research report; it presents background and context but does not itself generate empirical evidence or conclusions that can be independently evaluated.
Quoted from the source exactly as published.
This commentary identifies adipolin as a candidate biomarker worthy of investigation in paediatric obesity and vascular dysfunction, but does not itself provide evidence to guide clinical practice. Clinicians should await results from the primary studies cited (particularly Jin et al.) before considering adipolin measurement in clinical care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
In the past three decades, the global combined prevalence of pediatric obesity has tripled, and in 2021, 93.1 million children aged 5–14 years were diagnosed with obesity. 1 Obesity-related comorbidities, such as cardiometabolic complications, increase with age and with the severity of obesity. 2 Cardiovascular complications are thought to be a result of multifactorial mechanisms, such as oxidative stress, reduced nitric oxide, and chronic low-grade inflammation. Accumulation of excessive macronutrients in adipose tissue leads to the excessive release of inflammatory mediators such as interleukin (IL)-6, IL-1β, tumor necrosis factor-α (TNF-α), leptin, and monocyte chemoattractant protein-1 (MCP-1). MCP-1 reduces the production of adiponectin. 3 Recently, adipolin, which is encoded by the FAM132A gene, has been found to have beneficial metabolic effects such as improving insulin resistance and reducing proinflammatory gene expression in obese mice. 4 However, the correlation between adipolin levels and obesity is conflicting in adults and children. While the older obese population has reduced adipolin levels, 5 a recent article by Jin et al. 6 demonstrates that children with obesity have elevated adipolin levels. Jin et al.’s article “Serum FAM132A/Adipolin Correlates with Endothelial Dysfunction in Children with Obesity” in the recent issue of Pediatric Research represents the initial step in elucidating the relationship between FAM132A levels and markers of endothelial dysfunction. 6 In this commentary, we evaluate the strengths and limitations of this study and propose areas for future research.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.